dc.contributor | Departament de Salut |
dc.contributor.author | Reig-Viader, Rita |
dc.contributor.author | Giménez-García, Emmanuel |
dc.date.accessioned | 2020-02-19T10:12:06Z |
dc.date.available | 2020-02-19T10:12:06Z |
dc.date.issued | 2019 |
dc.identifier.citation | Reig-Viader R, Giménez E. MALDI-TOF en el diagnóstico de las resistencias a antibióticos. Barcelona: Agència de Qualitat i Avaluació Sanitàries de Catalunya; 2019. (Informes, estudios e investigación). |
dc.identifier.other | 731-19-057-8 |
dc.identifier.uri | https://hdl.handle.net/11351/4656 |
dc.description | MALDI-TOF; Mass spectrometry technology; Diagnosis; Infectious disease |
dc.description.abstract | In any infectious disease, the administration of a suitable antibiotic
treatment in the appropriate and necessary moment is key for the care
and evolution of the patient, and also to reduce its morbimortality.
Because of that, it is determining that the diagnostic and treatment of
the disease were carried out as soon as possible. The increasing
incidence of caused infections for resistant pathogens (or multiresistant)
to the available antibiotics provokes a high probability of error in its
treatment. For instance it happens in the cases of severe infections, the
treatment of which, because of being urgent, is usually chosen
empirically, without expecting the outcomes of sensitivity. In fact, it is
estimated that the choice of the antibiotic, the indications and the
duration of the treatment for the infectious diseases are erroneous in
30-50% of the cases.
This not only it drives to an increase of the morbimortality of these
diseases, but, still more important, it promotes the appearance and
dissemination of antimicrobic resistances among the pathogenic
microorganisms. Precisely, the high error rate in the treatment of the
infectious diseases, together with the uncontrolled use of antibiotics
in the last decades has caused that today there is an alarming number
of resistant pathogens and, consequently, an increase of the incidence
of infectious diseases of difficult treatment and the mortality
associated with these ones. Therefore, it is preferential to adopt
measures that allow to revert and to control this situation. |
dc.language.iso | spa |
dc.publisher | Agència de Qualitat i Avaluació Sanitàries de Catalunya |
dc.publisher | Ministerio de Sanidad, Consumo y Bienestar Social |
dc.relation.ispartofseries | Informes, estudios e investigación; |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Espectrometria de masses |
dc.subject | Infecció - Diagnòstic |
dc.subject | Resistència als medicaments |
dc.subject.mesh | Mass Spectrometry |
dc.subject.mesh | Infection |
dc.subject.mesh | /diagnosis |
dc.subject.mesh | Drug Resistance, Bacterial |
dc.title | MALDI-TOF en el diagnóstico de las resistencias a antibióticos |
dc.title.alternative | MALDI-TOF mass spectrometry technology in the diagnosis of antibiotic resistance |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | espectrometría de masas |
dc.subject.decs | infección |
dc.subject.decs | /diagnóstico |
dc.subject.decs | farmacorresistencia bacteriana |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQUAS), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |